These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16320017)

  • 21. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
    Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 24. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
    Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
    Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Agents inhibiting steroid biosynthesis--aminoglutethimide and o,p'-DDD].
    Aida M; Miura K
    Nihon Rinsho; 1974 Nov; 32(11):3257-61. PubMed ID: 4375206
    [No Abstract]   [Full Text] [Related]  

  • 26. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Barzon L; Fallo F; Sonino N; Daniele O; Boscaro M
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1488-9. PubMed ID: 10199802
    [No Abstract]   [Full Text] [Related]  

  • 27. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 28. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ; Somberg LB
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
    Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
    Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current therapeutic concepts--Cushing's syndrome.
    Kishi DT
    J Am Pharm Assoc; 1975 May; 15(5):261-70. PubMed ID: 164494
    [No Abstract]   [Full Text] [Related]  

  • 32. Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure.
    Kojori F; Cronin CM; Salamon E; Burym C; Sellers EA
    J Pediatr Endocrinol Metab; 2011; 24(3-4):203-4. PubMed ID: 21648293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mitotane as possible cause of acute intermittent porphyria].
    von Eyben FE
    Ugeskr Laeger; 2011 Sep; 173(37):2268-9. PubMed ID: 21917227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
    Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
    Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ACTH and aminoglutethimide administration on the morphological and functional responses of rat adrenal zona fasciculata to a prolonged treatment with 4-aminopyrazolo-pyrimidine.
    Mazzocchi G; Robba C; Meneghelli V; Nussdorfer GG
    J Anat; 1987 Oct; 154():55-61. PubMed ID: 2833484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.
    De León DD; Lange BJ; Walterhouse D; Moshang T
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4452-6. PubMed ID: 12364417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The medical treatment of Cushing's syndrome.
    Miller JW; Crapo L
    Endocr Rev; 1993 Aug; 14(4):443-58. PubMed ID: 7693447
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
    Mayor-Ibarguren A; Roldán-Puchalt MC; Gómez-Fernández C; Albízuri-Prado F; Álvarez-Escola C
    JAMA Dermatol; 2016 Jan; 152(1):109-11. PubMed ID: 26444320
    [No Abstract]   [Full Text] [Related]  

  • 40. Letting post-marketing bridge the evidence gap: the case of orphan drugs.
    Joppi R; Gerardi C; Bertele' V; Garattini S
    BMJ; 2016 Jun; 353():i2978. PubMed ID: 27335134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.